- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07726654
The Longitudinal Cohort of Cerebral Small Vessel Disease in Ruijin Hospital
The goal of this observational study is to learn about neuroimage and biomarkers in the cerebral small vessel disease. The main questions it aims to answer are:
- How does neurovascular coupling change during the progression of CSVD?
- How is the pattern/mapping of alterations in CSVD biomarkers? Participants will be observed and visit the research center annually to perform multi-modal MRI, PET, neuropsychological tests, and blood tests.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This observational study recruits participants with cerebral small vessel disease (CSVD) from hospitals and community-based populations. Healthy volunteers will also be recruited as controls. Longitudinal follow-up of these participants will help clarify the significance of neuroimaging and biological biomarkers during the development and progression of CSVD.
The investigators aim to establish a longitudinal cohort covering the spectrum of CSVD and identify key biomarkers associated with disease progression and cognitive decline. All participants will undergo multimodal MRI, PET imaging (optional) with different tracers, and blood biomarker assessments. Using multimodal MRI, the investigators will investigate alterations in neurovascular coupling and their role in the pathophysiology of CSVD. In addition, PET imaging (optional) and blood biomarkers will be used to characterize the spatial and temporal patterns of disease-related biomarker changes. Furthermore, additional neuroimaging and digital biomarkers will be evaluated within the cohort to improve disease characterization and prognostic prediction.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200025
- Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
-
Kontakt:
- Jingyan Tian, Dr
- Telefonnummer: 13671865057
- E-mail: tjy11488@rjh.com.cn
-
Ledende efterforsker:
- Jingwen Jiang, Dr.
-
Underforsker:
- Binyin Li, Dr.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Age ≥18 years.
Evidence of cerebral small vessel disease (CSVD) on brain MRI, meeting at least one of the following imaging criteria:
- White matter hyperintensities (WMH) with a total Fazekas score ≥2;
- Fazekas score =1 with at least two vascular risk factors (hypertension, hyperlipidemia, diabetes mellitus, obesity, current smoking, or a history of vascular events other than stroke);
- Fazekas score =1 accompanied by the presence of lacunes;
- Imaging evidence of a recent subcortical lacunar infarction.
- Independent in activities of daily living (modified Rankin Scale [mRS] ≤2).
- Able and willing to provide written informed consent.
Exclusion Criteria:
- Acute ischemic stroke with a diffusion-weighted imaging (DWI) lesion >20 mm in diameter.
- Acute intracerebral hemorrhage.
- Acute subarachnoid hemorrhage, a history of aneurysmal subarachnoid hemorrhage or cerebrovascular malformation, or the presence of an untreated intracranial aneurysm >3 mm in diameter.
- Previously diagnosed neurodegenerative disorders, such as Alzheimer's disease (AD) or Parkinson's disease (PD).
- Definite non-vascular white matter diseases, including multiple sclerosis, adult-onset leukodystrophy, metabolic encephalopathy, or other non-vascular white matter disorders.
- Major psychiatric disorders diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
- Contraindications to MRI (e.g., severe claustrophobia or MRI-incompatible implants).
- Severe systemic diseases (e.g., active malignancy) with an expected life expectancy of less than 5 years.
- Inability to complete scheduled follow-up because of geographic, logistical, or other reasons.
- Concurrent participation in another interventional clinical trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Cognitively Normal
Participants do not have cognitive impairment.
|
|
Cerebral small vessel disease without dementia
Participants have vascular cognitive impairment, but no cognitive impairment
|
|
Vascular Dementia (VaD)
Participants have vascular cognitive impairment or difficulty in daily activity.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Global cognitive ability
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Mini-mental state examination
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Executive function
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Clock drawing test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Visual memory
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Rey-Osterich complex figure test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Short-term memory
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Auditory verbal learning test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Executive memory
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Symbol-digit test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Spatial executive function
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Trail making test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Naming ability
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Boston naming test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Language ability
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Language fluency test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Sleep quality
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Sleep disorder
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Movement ability
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Part III of the Unified Parkinson's Disease Rating Scale
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Brain volume
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Annual changes of volumes of brain
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Connectivity integrity of the neural circuit
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Annual changes of hippocampus related neural connectivity
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Volume of white matter lesions
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Structural and functional MRI measures, including arterial spin labeling (ASL), diffusion MRI (dMRI), susceptibility-weighted imaging (SWI) and fluid-attenuated inversion recovery (FLAIR).
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- RJNeuroBank-SVD
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .